Compare MWH & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MWH | BLCO |
|---|---|---|
| Founded | 2008 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Ophthalmic Goods |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 6.0B |
| IPO Year | N/A | 2022 |
| Metric | MWH | BLCO |
|---|---|---|
| Price | $28.92 | $15.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 12 |
| Target Price | ★ $35.10 | $18.55 |
| AVG Volume (30 Days) | ★ 658.9K | 380.7K |
| Earning Date | 03-19-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,101,000,000.00 |
| Revenue This Year | $51.54 | $8.63 |
| Revenue Next Year | $14.28 | $5.58 |
| P/E Ratio | $50.60 | ★ N/A |
| Revenue Growth | N/A | ★ 6.47 |
| 52 Week Low | $26.60 | $10.45 |
| 52 Week High | $33.00 | $18.92 |
| Indicator | MWH | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 46.51 | 34.23 |
| Support Level | $27.24 | $14.39 |
| Resistance Level | $30.66 | $17.66 |
| Average True Range (ATR) | 1.60 | 0.49 |
| MACD | 0.07 | -0.12 |
| Stochastic Oscillator | 43.29 | 1.16 |
SOLV Energy Inc is a provider of infrastructure services to the power industry, including engineering, procurement, construction, testing, commissioning, operations, maintenance and repowering. It specializes in designing, building and maintaining utility-scale solar and battery storage projects and related T&D infrastructure. The company's projects include: The Eldorado Solar Project, Gravel Pit Solar Project, and Vikings Solar-plus-Storage Project. It operates in one reportable segment which derives revenue through providing EPC, O&M and Development services throughout the Unites Sates. The company derives maximum of revenue from its EPC contracts.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.